Interstitial Lung Disease clinical trials at UC Irvine

1 research study open to eligible people

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
open to eligible people ages 40 years and up
Study RIN-PF-301 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period.
Orange, California and other locations

Our lead scientists for Interstitial Lung Disease research studies include Bassam Yaghmour, MD.

Last updated: February 14, 2023

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis